Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124450752 | 12445075 | 2 | F | 20160423 | 20160602 | 20160607 | 20160804 | PER | US-ASTRAZENECA-2016SE46367 | ASTRAZENECA | 22949.00 | DY | Y | 101.60000 | KG | 20160804 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124450752 | 12445075 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 106 | MG | FT0054 | 22200 | 2 | MG | /wk | |||||
| 124450752 | 12445075 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | U | 21773 | 10 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124450752 | 12445075 | 1 | Type 2 diabetes mellitus |
| 124450752 | 12445075 | 2 | Type 2 diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124450752 | 12445075 | Device malfunction | |
| 124450752 | 12445075 | Glycosylated haemoglobin increased | |
| 124450752 | 12445075 | Injection site nodule | |
| 124450752 | 12445075 | Underdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124450752 | 12445075 | 1 | 2015 | 0 |